Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma

Xu Zhang; Zhiguo Zhang

doi:10.1016/j.trecan.2019.10.009

Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma

Trends Cancer. 2019 Dec;5(12):799-808. doi: 10.1016/j.trecan.2019.10.009. Epub 2019 Nov 9.

Authors

Xu Zhang¹, Zhiguo Zhang²

Affiliations

¹ Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
² Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: zz2401@cumc.columbia.edu.

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric tumor with no currently available treatment options. More than 60-70% DIPG tumors harbor heterozygous mutations at genes encoding histone H3 proteins that replace lysine 27 with methionine (K27M). In this review, we discuss how K27M mutation reprograms the cancer epigenome to lead to tumorigenesis, and highlight potential drug targets and therapeutic agents for DIPG.

Keywords: H3K27M; diffuse intrinsic pontine glioma; oncohistone mutation; poised enhancers.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Diffuse Intrinsic Pontine Glioma / physiopathology*
Histones / metabolism*
Humans
Mutation

Substances

Histones

Grants and funding

R01 CA204297/CA/NCI NIH HHS/United States